Presented at SNMMI 2022 Annual Meeting
Norbert Wiedemann1, Frédéric Massière1, Franck Brichory1, Aileen Hoehne2, Frank Osterkamp2, InêsBorrego1, Antoine Attinger1
1Debiopharm International SA, Lausanne, Switzerland
23B Pharmaceuticals GmbH, Germany
- The transmembrane metalloproteaseCarbonic Anhydrase IX (CAIX) represents an attractive diagnostic and therapeutic target in hypoxic solid tumors such as Colorectal Cancer (CRC) and clear cell Renal Cell Carcinoma (ccRCC), with limited expression in healthy organs.
- DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage that can be labelled with different radionuclides for theranostic purposes
- Here we report CAIX expression in CRC and ccRCC human tumorsamples and evaluate for the first time the in vitroand in vivo therapeutic and diagnostic performance of [177Lu]Lu-DPI-4452 and [68Ga]Ga-DPI-4452